MediWound Projects Strong Revenue Growth Through 2028, Provides Positive Clinical & Operational Updates

summarizeSummary

MediWound provided a corporate update and financial outlook, projecting significant revenue growth through 2028, alongside positive clinical progress for EscharEx and operational advancements for NexoBrid. The company also reported a strong cash position of $54 million with no debt.

check_boxKey Events

• Strong Revenue Guidance

  Updated financial outlook projects revenue growth from $17 million in 2025 to $24–26 million in 2026, $32–35 million in 2027, and $50–55 million by 2028.

• EscharEx Clinical Progress

  Interim assessment and enrollment completion for the VALUE Phase III trial in venous leg ulcers (VLUs) are expected by year-end 2026, with plans to initiate a Phase II study in diabetic foot ulcers (DFUs) and an investigator-initiated trial (IIT) for pressure ulcers (PUs) in 2026.

• NexoBrid Operational Expansion

  The expanded NexoBrid manufacturing facility is now fully operational, increasing production capacity sixfold, with regulatory approvals targeted for 2026.

• Healthy Balance Sheet

  The company reported a cash position of $54 million as of December 31, 2025, with no outstanding debt.

auto_awesomeAnalysis

MediWound's corporate update and financial outlook ahead of the J.P. Morgan Healthcare Conference present a highly positive trajectory for the company. The updated revenue guidance, projecting a substantial increase from $17 million in 2025 to $50-55 million by 2028, signals strong anticipated growth driven by its product pipeline. This long-term outlook, coupled with a healthy cash position of $54 million and no debt, provides a solid financial foundation. Furthermore, the progress in the EscharEx Phase III trial and plans for expansion into additional chronic wound indications, alongside the operational readiness of the expanded NexoBrid manufacturing facility, underscore significant advancements in its core product development and commercialization efforts. Investors should view this comprehensive update as a strong indicator of future potential and operational execution.